Links
Archives
Sunday, July 30, 2006
About inflammatory bowel disease
Useful Serologic markers: (from Medscape)
"Recent attention has been paid to 2 serologic markers, anti-Saccharomyces cerevisiae antibody (ASCA) and perinuclear anti-neutrophilic cytoplasmic antibody (pANCA), which have been proposed as screening tools for patients who present with signs and symptoms of IBD. The Prometheus IBD First Step Generation II (Prometheus Laboratories; San Diego, California) is a commercially available serologic panel of antibodies, including pANCA/ANCA, ASCA IgA, ASCA IgG, and anti-OmpC (outer membrane porin from Escherichia coli) IgA. This test is intended to exclude the presence of IBD in patients with nonspecific symptoms. (The pANCA and ASCA assays are offered commercially through several other companies as well, but these other serologic panels do not include some of the other antibodies, such as anti-OmpC.)"
Along with the discovery of anti-CBir1 flagellin, another technique has been introduced in an attempt to increase diagnostic ability. The Smart Diagnostic Algorithm technology (personal communication with Prometheus Laboratories, 2006) has now been incorporated into the diagnostic armamentarium.
(Lois A, Waldleigh F, Neri B. Development of a hybrid algorithm based on learning classifiers that improves diagnosis of inflammatory bowel disease and differentiation between Crohn's and ulcerative colitis in a multi-marker system. Gastroenterology. 2006;130:Abstract M 1198.)
"Recent attention has been paid to 2 serologic markers, anti-Saccharomyces cerevisiae antibody (ASCA) and perinuclear anti-neutrophilic cytoplasmic antibody (pANCA), which have been proposed as screening tools for patients who present with signs and symptoms of IBD. The Prometheus IBD First Step Generation II (Prometheus Laboratories; San Diego, California) is a commercially available serologic panel of antibodies, including pANCA/ANCA, ASCA IgA, ASCA IgG, and anti-OmpC (outer membrane porin from Escherichia coli) IgA. This test is intended to exclude the presence of IBD in patients with nonspecific symptoms. (The pANCA and ASCA assays are offered commercially through several other companies as well, but these other serologic panels do not include some of the other antibodies, such as anti-OmpC.)"
Along with the discovery of anti-CBir1 flagellin, another technique has been introduced in an attempt to increase diagnostic ability. The Smart Diagnostic Algorithm technology (personal communication with Prometheus Laboratories, 2006) has now been incorporated into the diagnostic armamentarium.
(Lois A, Waldleigh F, Neri B. Development of a hybrid algorithm based on learning classifiers that improves diagnosis of inflammatory bowel disease and differentiation between Crohn's and ulcerative colitis in a multi-marker system. Gastroenterology. 2006;130:Abstract M 1198.)
Posted by: Ds20040999 / 11:49 PM 
